Drug intelligence / Profile preview

CIN244

Development stage: Unknown
Lead developer: Cincera Therapeutics
Modality: Small Molecules

Overview

CIN244 is a novel small molecule drug candidate developed by Cincera Therapeutics for the treatment of fibrotic diseases. It acts as an inhibitor of the MRTF/SRF (myocardin-related transcription factor/serum response factor) pathway, which plays a key role in the development and progression of fibrosis. Preclinical studies have demonstrated that CIN244 exhibits antifibrotic activity, particularly in models of liver, lung, and renal fibrosis. The compound is currently at the discovery stage and has not yet entered clinical trials[1][2][3][8].

Targets

SRF (Serum response factor)

Beyond the preview

Go deeper on CIN244.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIN244.

Explore the full profile